Rein Therapeutics Inc RNTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.97
- Day Range
- $0.95–1.00
- 52-Week Range
- $0.86–2.18
- Bid/Ask
- $0.96 / $1.05
- Shares Outstanding
- 85.54M
- Market Cap
- $85.35M
- Volume/Avg
- 313,493 / 777,178
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.reintx.com
Valuation
|
Metric
|
RNTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RNTX
|
|---|---|
Quick Ratio | 0.33 |
Current Ratio | 0.40 |
Interest Coverage | — |
Quick Ratio
RNTX
Profitability
|
Metric
|
RNTX
|
|---|---|
Return on Assets (Normalized) | −44.22% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
RNTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#$p$#m< | LOCK|QFmf | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|T<^yVP | LOCK|$&TK | $70B | |||
| argenx SE ADR
ARGX
| LOCK|#&MzHZ | LOCK|M?t | $57B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<NV<M@L | LOCK|dwJW | $42B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&kkgXJ# | LOCK|#%< | $35B | |||
| Moderna Inc
MRNA
| LOCK|wGb>h@k | LOCK|q$% | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Ttk?%d! | LOCK|$xx@@ | $26B | |||
| Incyte Corp
INCY
| LOCK|<#%VyqB | LOCK|<$ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|@<hrx^ | LOCK|H#S | $24B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Xjrj?> | LOCK|P!V | $18B |
United States